{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:49:32Z","timestamp":1781304572661,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1136\/ijgc-2022-003570","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:02:18Z","timestamp":1661511738000},"page":"1583-1591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Do autoimmune diseases influence the onset and progression of ovarian cancer? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-6379","authenticated-orcid":false,"given":"Roxanne","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vankerckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmine","family":"Verreet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Ceusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-4339","authenticated-orcid":false,"given":"An","family":"Coosemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003570_bb0010","unstructured":"National Cancer Institute, Surveillance Research Program . SEER*Explorer: an interactive website for SEER cancer statistics. Available: https:\/\/seer.cancer.gov\/explorer\/ [Accessed 09 May 2022]."},{"key":"10.1136\/ijgc-2022-003570_bb0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003570_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-218","article-title":"A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies","volume":"10","author":"Bot","year":"2012","journal-title":"J Transl Med"},{"key":"10.1136\/ijgc-2022-003570_bb0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1136\/ijgc-2022-003570_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological configuration of ovarian carcinoma: features and impact on disease outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2022-003570_bb0040","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2022-003570_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01273","article-title":"Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer","volume":"10","author":"Baert","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ijgc-2022-003570_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","article-title":"Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis","volume":"147","author":"Yuan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003570_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2019.02.014","article-title":"Combining conventional therapy with immunotherapy: arisky business?","volume":"113","author":"Coosemans","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1136\/ijgc-2022-003570_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1136\/ijgc-2022-003570_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1136\/ijgc-2022-003570_bb0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1136\/ijgc-2022-003570_bb0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2012.07.100","article-title":"Effect of autoimmune diseases on risk and survival in female cancers","volume":"127","author":"Hemminki","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003570_bb0085","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0090","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology"},{"key":"10.1136\/ijgc-2022-003570_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jnnp.2009.175463","article-title":"Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies","volume":"81","author":"Fois","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1136\/ijgc-2022-003570_bb0100","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia, Canada","volume":"135","author":"Kingwell","year":"2012","journal-title":"Brain"},{"key":"10.1136\/ijgc-2022-003570_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1136\/ijgc-2022-003570_bb0110","first-page":"887","article-title":"Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California","volume":"19","author":"Parikh-Patel","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1136\/ijgc-2022-003570_bb0115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1191\/096120301678646128","article-title":"Systemic lupus erythematosus and the risk of malignancy","volume":"10","author":"Cibere","year":"2001","journal-title":"Lupus"},{"key":"10.1136\/ijgc-2022-003570_bb0120","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ijgc-2022-003570_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000156","article-title":"Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients","volume":"3","author":"Ramsey-Goldman","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ijgc-2022-003570_bb0130","doi-asserted-by":"crossref","first-page":"1150.e1","DOI":"10.1016\/j.amjmed.2010.08.006","article-title":"Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan","volume":"123","author":"Chen","year":"2010","journal-title":"Am J Med"},{"key":"10.1136\/ijgc-2022-003570_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1422.008","article-title":"Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center","volume":"1108","author":"Tarr","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1136\/ijgc-2022-003570_bb0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03009740252937568","article-title":"Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus","volume":"31","author":"Bj\u00f6rn\u00e5dal","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1191\/0961203303lu443oa","article-title":"Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus","volume":"12","author":"Ragnarsson","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ijgc-2022-003570_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/03009742.2017.1384054","article-title":"Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up","volume":"47","author":"Tallbacka","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0155","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/art.30483","article-title":"High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort","volume":"63","author":"Dreyer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ijgc-2022-003570_bb0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10067-009-1332-7","article-title":"Incidence of cancer among female patients with systemic lupus erythematosus in Korea","volume":"29","author":"Kang","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780400424","article-title":"Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus","volume":"40","author":"Mellemkjaer","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ijgc-2022-003570_bb0170","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2188\/jea.JE20140197","article-title":"A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan","volume":"25","author":"Hsu","year":"2015","journal-title":"J Epidemiol"},{"key":"10.1136\/ijgc-2022-003570_bb0175","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/sj.bjc.6602611","article-title":"Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study","volume":"92","author":"Swerdlow","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0180","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1464-5491.2010.03011.x","article-title":"Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden","volume":"27","author":"Shu","year":"2010","journal-title":"Diabet Med"},{"key":"10.1136\/ijgc-2022-003570_bb0185","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/djg105","article-title":"Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden","volume":"95","author":"Zendehdel","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003570_bb0190","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc14-1996","article-title":"Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation","volume":"38","author":"Harding","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1136\/ijgc-2022-003570_bb0195","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"key":"10.1136\/ijgc-2022-003570_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10067-017-3676-8","article-title":"Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0205","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/1097-0142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1","article-title":"Pernicious anemia and subsequent cancer. A population-based cohort study","volume":"71","author":"Hsing","year":"1993","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0210","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/bjc.1996.195","article-title":"Pernicious anaemia and cancer risk in Denmark","volume":"73","author":"Mellemkjaer","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.14698","article-title":"Cancer risk in 892 089 patients with psoriasis in Korea: a nationwide population-based cohort study","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol"},{"key":"10.1136\/ijgc-2022-003570_bb0220","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ijgc-2022-003570_bb0225","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3899\/jrheum.160542","article-title":"Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study","volume":"43","author":"Costa","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ijgc-2022-003570_bb0235","first-page":"1001","article-title":"Risk of cancer among rheumatoid arthritis patients in California","volume":"20","author":"Parikh-Patel","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1136\/ijgc-2022-003570_bb0240","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor \u03b1 antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ijgc-2022-003570_bb0245","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","article-title":"Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study","volume":"34","author":"Berghen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0250","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/1756-185X.13655","article-title":"Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients","volume":"22","author":"Lim","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ijgc-2022-003570_bb0255","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/annrheumdis-2011-200402","article-title":"Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan","volume":"71","author":"Weng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ijgc-2022-003570_bb0260","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0265","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0270","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1572-0241.1999.01012.x","article-title":"Increased risk of cancer in ulcerative colitis: a population-based cohort study","volume":"94","author":"Karl\u00e9n","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ijgc-2022-003570_bb0275","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0016-5085(94)90807-9","article-title":"Crohn's disease and cancer: a population-based cohort study","volume":"107","author":"Persson","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1136\/ijgc-2022-003570_bb0280","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.21380","article-title":"Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden","volume":"17","author":"Shu","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ijgc-2022-003570_bb0285","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ecco-jcc\/jjw048","article-title":"Inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case-control IG-IBD study","volume":"10","author":"Biancone","year":"2016","journal-title":"ECCOJC"},{"key":"10.1136\/ijgc-2022-003570_bb0290","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R","article-title":"Extracolonic malignancies in inflammatory bowel disease","volume":"67","author":"Ekbom","year":"1991","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0295","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ijc.26454","article-title":"Reduced risk of breast, endometrial and ovarian cancer in women with celiac disease","volume":"131","author":"Ludvigsson","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003570_bb0300","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/gast.2002.36585","article-title":"Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis","volume":"123","author":"Askling","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1136\/ijgc-2022-003570_bb0305","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","article-title":"Incidence of cancer in a cohort of patients with primary Sjogren's syndrome","volume":"45","author":"Lazarus","year":"2006","journal-title":"Rheumatology"},{"key":"10.1136\/ijgc-2022-003570_bb0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","article-title":"A retrospective study of long-term outcomes in 152 patients with primary Sj\u00f6gren\u2019s syndrome: 25-year experience","volume":"14","author":"Abrol","year":"2014","journal-title":"Clin Med"},{"key":"10.1136\/ijgc-2022-003570_bb0315","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.revmed.2019.06.004","article-title":"Survenue de cancers au cours de la scl\u00e9rodermie syst\u00e9mique : facteurs de risque, impact sur la survie et revue de la litt\u00e9rature","volume":"40","author":"Catano","year":"2019","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"10.1136\/ijgc-2022-003570_bb0320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0248-8663(97)80804-1","article-title":"Systemic sclerosis and malignancy: assessment of risk factors associated with the development of cancer in 123 patients with systemic sclerosis","volume":"18","author":"Kyndt","year":"1997","journal-title":"La Rev M\u00e9decine Interne"},{"key":"10.1136\/ijgc-2022-003570_bb0325","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10067-016-3288-8","article-title":"Risk factors for malignancy in systemic sclerosis patients","volume":"35","author":"Ka\u015fifo\u011flu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ijgc-2022-003570_bb0330","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.18.01223","article-title":"Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study","volume":"37","author":"Bae","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003570_bb0335","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00432-020-03245-3","article-title":"Cancer risks in patients with vitiligo: a Mendelian randomization study","volume":"146","author":"Wen","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2022-003570_bb0340","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/eji.200526065","article-title":"Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis","volume":"35","author":"Haas","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1136\/ijgc-2022-003570_bb0345","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.15252\/embr.201643668","article-title":"LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination","volume":"18","author":"Sun","year":"2017","journal-title":"EMBO Rep"},{"key":"10.1136\/ijgc-2022-003570_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020305","article-title":"Opposite macrophage polarization in different subsets of ovarian cancer: observation from a pilot study","volume":"9","author":"Vankerckhoven","year":"2020","journal-title":"Cells"},{"key":"10.1136\/ijgc-2022-003570_bb0355","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/art.10365","article-title":"Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study","volume":"46","author":"Cooper","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ijgc-2022-003570_bb0360","doi-asserted-by":"crossref","first-page":"i65","DOI":"10.1136\/ard.2009.117135","article-title":"Treg and lupus","volume":"69","author":"Bonelli","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ijgc-2022-003570_bb0365","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI112295","article-title":"High glucose induces DNA damage in cultured human endothelial cells","volume":"77","author":"Lorenzi","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-2022-003570_bb0370","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0029-7844(96)00226-8","article-title":"Epithelial ovarian cancer risk among women with polycystic ovary syndrome","volume":"88","author":"Schildkraut","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003570_bb0375","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2014.04.006","article-title":"Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of type 1 diabetes mellitus patients","volume":"153","author":"Whitfield-Larry","year":"2014","journal-title":"Clin Immunol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:27:32Z","timestamp":1753234052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24007539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1048891X24007539"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003570","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do autoimmune diseases influence the onset and progression of ovarian cancer? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}